United States · Investor

Alexandria Real Estate Equities

Last cheque observed Jun 2026; 107 cheques on record.

Email

Deploying nowVC firm

SeedSeries ASeries BMental HealthWell-beingHealthtech

Deploying now
67%of best year2cheques in 12 months, 107 on record
Since the last cheque142days00hrs00min00sec
Median round$45MRounds led1 of 107Sole investor1 roundsExits1 from the portfolioMostly inUnited States, 93%
Pitch Alexandria Real Estate Equities

Alexandria Real Estate Equities highlights

  1. 01

    2 cheques in the last 12 months

  2. 02

    Mostly Series B and Series A: 81% of its rounds

  3. 03

    Sole investor in 1 rounds, median $7.0M

  4. 04

    1 exits from the portfolio

What they do

Type
VC firm (from a list, unverified)
Cheque size
Not stated
Stages
SeedSeries ASeries BGrowthPre-IPO
Sectors
Mental HealthWell-beingHealthtech
Based in
Pasadena, United States
Cold pitches
Not stated

The record

Every round we can evidence, newest first107 appearances

  1. 2026

    2 rounds

  2. Jun
    SonoTheraSeries B · US · Ventureburn$125MWith 10 others
  3. Apr
    Sidewinder TherapeuticsSeries B · US · Ventureburn$137MWith 8 others
  4. 2025

    2 rounds

  5. May
    HAYA TherapeuticsSeries A · CH · Firms' own news pages$65MWith 11 others
  6. Feb
    Eikon TherapeuticsSeries D · US · Crunchbase News$351MWith 4 others
  7. 2024

    2 rounds

  8. Oct
    March BiosciencesSeries A · US · 4BIO Capital$28MWith 10 others
  9. Mar
    Capstan TherapeuticsSeries B · US · Firms' own news pages$175MWith 15 others
  10. 2023

    1 round

  11. May
    Myeloid Therapeutics, Inc.Series C · US · Hatteras Venture Partners$73MWith 5 others
  12. 2021

    2 rounds

  13. Sept
    KytopenSeries A · US · Firms' own news pages$30MWith 6 others
  14. Jun
    Veralox TherapeuticsSeries A · US · Hatteras Venture Partners$17MWith 8 others
  15. 2019

    21 rounds

  16. Dec
    Aspen NeuroscienceSeed · US · FinSMEs$6.5MWith 5 others
  17. Dec
    Jasper TherapeuticsSeries A · US · FinSMEs$35MWith 3 others
  18. Dec
    ImCheck TherapeuticsSeries B · FR · FinSMEs$53MWith 9 others
  19. Nov
    ImmunitasSeries A · US · FinSMEs$39MWith 4 others
  20. Oct
    Adaptive PhageUS · Vcnewsdaily$7.0MSole investor
  21. Oct
    Molecular AssembliesSeries A · US · FinSMEs$12MWith 3 others
  22. Sept
    Boundless BioSeries A · US · FinSMEs$46MWith 5 others
  23. Jul
    X-VaxSeries A · US · FinSMEs$56MWith 5 others
  24. Jul
    Cradle GenomicsSeries A · US · FinSMEs$17MWith 5 others
  25. Jul
    GNS HealthcareSeries D · US · FinSMEs$23MWith 5 others
  26. Jun
    Blackthorn TherapeuticsSeries B · US · FinSMEs$76MWith 11 others
  27. Jun
    Strand TherapeuticsSeed · US · FinSMEs$6.0MWith 2 others
  28. Apr
    Arrakis TherapeuticsSeries B · US · FinSMEs$75MWith 13 others
  29. Mar
    Prevail TherapeuticsSeries B · US · Medcitynews$50MWith 10 others
  30. Mar
    Cardea BioSeries A · US · FinSMEs$7.8MLed
  31. Mar
    Karuna TherapeuticsSeries B · US · FinSMEs$68MWith 8 others
  32. Mar
    GencoveUS · FinSMEs$3.0MWith 4 others
  33. Jan
    Dewpoint TherapeuticsSeries A · US · FinSMEs$60MWith 4 others
  34. Jan
    GreenLigh BiosciencesUS · FinSMEs$50MWith 4 others
  35. Jan
    Frequency TherapeuticsSeries B · US · FinSMEs$42MWith 6 others
  36. Jan
    Tiburio TherapeuticsSeries A · US · FinSMEs$31MWith 3 others
  37. 2018

    23 rounds

  38. Dec
    KallyopeSeries B · US · FinSMEs$21MWith 6 others
  39. Nov
    Rheostat TherapeuticsSeries A · US · FinSMEs$23MWith 5 others
  40. Nov
    NextCureSeries B · MD · Pehub$93MWith 12 others
  41. Nov
    RibometrixSeries A · US · FinSMEs$30MWith 10 others
  42. Oct
    Stoke TherapeuticsSeries B · US · FinSMEs$90MWith 7 others
  43. Oct
    RgenixSeries C · US · FinSMEs$40MWith 4 others
  44. Sept
    KSQ TherapeuticsSeries C · US · FinSMEs$80MWith 7 others
  45. Sept
    Silverback TherapeuticsSeries A · US · GeekWire$38MWith 1 other
  46. Aug
    Magnolia NeuroscienceSeries A · US · FinSMEs$31MWith 10 others
  47. Aug
    InariSeries B · US · FinSMEs$40MWith 2 others

An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.

The team

We hold 17 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.

Exits from the portfolio

Companies it backed that were later bought or listed1 in all

GoAhead SoftwareBought by Oracle CorporationUndisclosedSept 2011

An exit counts when it came after the firm's first round in the company. From historical deal records.

Who they invest alongside

The investors most often in the same rounds as Alexandria Real Estate Equities. A count of rooms they were both in, not a relationship either has claimed.

ARCH Venture PartnersVC firm22rounds togetherPolaris PartnersVC firm9rounds togetherVersant VenturesVC firm8rounds togetherAmgenCorporate VC7rounds togetherEcoR1 CapitalPrivate equity7rounds togetherOVP Venture PartnersVC firm7rounds togetherOrbiMedPrivate equity7rounds togetherPfizerCorporate VC7rounds togetherAmgen VenturesGrowth equity6rounds togetherArchHedge fund6rounds togetherCanaanVC firm6rounds togetherGoogle VenturesCorporate VC6rounds together

Recently backed

The latest companies Alexandria Real Estate Equities put money into.

SonoThera$125M · Jun 2026Sidewinder Therapeutics$137M · Apr 2026HAYA Therapeutics$65M · May 2025Eikon Therapeutics$351M · Feb 2025March Biosciences$28M · Oct 2024Kytopen$30M · Sept 2021

Quick answers about Alexandria Real Estate Equities

What does Alexandria Real Estate Equities invest in?

Alexandria Real Estate Equities invests most often at Series B and Series A (81% of the rounds on record), in sectors such as Mental Health, Well-being and Healthtech.

How active is Alexandria Real Estate Equities?

107 investments on record, 2 of them in the last 12 months, and it led 1. The most recent was in Jun 2026.

What has Alexandria Real Estate Equities invested in recently?

Its most recent investments on record: SonoThera (Series B, Jun 2026), Sidewinder Therapeutics (Series B, Apr 2026) and HAYA Therapeutics (Series A, May 2025).

How big are Alexandria Real Estate Equities's cheques?

The median round it joins is $45M.

Does Alexandria Real Estate Equities lead rounds?

Sometimes: it led 1 of its 107 investments on record (1%).

Where does Alexandria Real Estate Equities invest?

Most of the companies it backs are in the United States (93%).

Is Alexandria Real Estate Equities investing now?

Yes: it is actively investing, with 2 investments in the last 12 months.

Who does Alexandria Real Estate Equities invest alongside?

Most often ARCH Venture Partners (22 rounds together), Polaris Partners (9 rounds together) and Versant Ventures (8 rounds together).

Raising now?

Find the investors who back rounds like yours, and keep every conversation on one fundraising board.

Find similar investorsOpen your CRM

Built from the rounds we watched, its filings and its own website, refreshed every night. How we count · Report a correction · Is this your firm? Claim it